Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04426695 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 2,252
- Enrollment target
NCT04426695 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,252 participants.
The verdict
NCT04426695, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2,252 participants
- Enrollment target
Study Summary
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) * To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 * To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation Phase 1/2 (Cohort 1) * To exclude futility of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
Interventions
- DRUG Placebo
- DRUG REGN10933+REGN10987 combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,252 participants |
| Start Date | 2020-06-10 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04426695
The ClinicalTrials.gov registry entry for NCT04426695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2,252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04426695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04426695 about?
NCT04426695 is a clinical study titled "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19". The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) * To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 * To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or...
What is the current status of trial NCT04426695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2,252 participants. The study started on 2020-06-10. Estimated completion is 2021-10-22.
What interventions are being tested in trial NCT04426695?
The interventions under investigation include: Placebo (DRUG), REGN10933+REGN10987 combination therapy (DRUG).
Who is sponsoring clinical trial NCT04426695?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.